Results 171 to 180 of about 9,905,323 (311)

Presenting a sham treatment as personalised increases the placebo effect in a randomised controlled trial. [PDF]

Elife, 2023
Sandra DA, Olson JA, Langer EJ, Roy M.
europepmc   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Arthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin   +12 more
wiley   +1 more source

Beyond the placebo effect: a systematic review and a network meta-analysis of treatment strategies for vulvodynia. [PDF]

BMC Womens Health
Spinillo A, Dominoni M, Tiranini L, Cassani C, Nappi RE, Gardella B.   +5 more
europepmc   +1 more source

Harnessing the placebo effect to enhance emotion regulation effectiveness and choice. [PDF]

Sci Rep, 2023
Shafir R, Israel M, Colloca L.
europepmc   +1 more source

Behavioral Incentives for Exercise and Intra‐Articular Glucocorticoids for Knee Osteoarthritis: Results From a Factorially Designed Pragmatic Randomized Clinical Trial

Arthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to determine the benefit of a behaviorally designed incentive program and glucocorticoid injections in reducing symptoms and promoting physical activity in patients with knee osteoarthritis (KOA). Methods This was a pragmatic, multisite, factorially designed, blinded, randomized clinical trial.
Joshua F. Baker, Katherine D. Wysham, Mercedes Quinones, Bryant R. England, Kaitian Jin, Marianna Olave, Sarah Wetzel, Rachel L. Gillcrist, Criswell Lavery, Natalie Keller, Bridget Kramer, Bibianna Ateh, Hannah Brubeck, Daniel K. White, Alexis Ogdie, Rui Xiao, Tuhina Neogi, Carla R. Scanzello   +17 more
wiley   +1 more source

The Placebo Effect in Rare Disease Clinical Trials: Measurement, Impact, and Statistical Approaches for Patient-as-Own-Control Designs. [PDF]

Clin Transl Sci
Summar ML, Woodcock J.
europepmc   +1 more source

Cold water immersion after a soccer match: Does the placebo effect occur? [PDF]

Front Physiol, 2023
Nasser N, Zorgati H, Chtourou H, Guimard A.   +3 more
europepmc   +1 more source

The American College of Rheumatology Updated Recommended Methods for Development of Disease Classification and Response Criteria

Arthritis &Rheumatology, EarlyView.
Disease classification criteria and response criteria are important tools in the conduct of observational studies and clinical trials for rheumatic diseases. This paper updates methodologic guidance for classification and response criteria funded, developed and/or endorsed by the American College of Rheumatology (ACR), incorporating contemporary ...
Sindhu R. Johnson, Tuhina Neogi, Amy S. Turner, Jaime Guzman, Zahi Touma   +4 more
wiley   +1 more source

Mechanisms of open and hidden placebo in stroke recovery: targeting neuroplasticity insights of the placebo effect - study protocol for a controlled, parallel, randomised clinical trial. [PDF]

BMJ Open
Ortega-Márquez J, Camargo L, Gianlorenço AC, Sosa W, Black-Schaffer R, Wang QM, Fregni F.   +6 more
europepmc   +1 more source

T cells, the Next Big Target in Axial Spondyloarthritis?

Arthritis &Rheumatology, EarlyView.
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight
Mansi K. Aparnathi, Nigil Haroon
wiley   +1 more source